EUCTR2013-000691-15-BE进行中（未招募）1 期
AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.
- •2. Previous enrollment in the bosutinib arm of one of the two Pfizer parent studies: B1871006 or B1871008. This includes:
- •a. Patients still receiving bosutinib in either study B1871006 or B1871008;
- •b. Patients who have discontinued bosutinib but are still in the long term follow up phase of the study B1871006 or B1871008;
- •c. Patients from study B1871006 who have discontinued bosutinib and have already completed the long term follow up period.
- •3. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •4. Male and female patients of childbearing potential must agree to use 2 highly effective methods of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
- •In order to be considered a female of non-childbearing potential the patient must meet at least 1 of the following criteria:
- •a. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause or;
- •a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state;
- •b. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •c. Have medically confirmed and documented ovarian failure.
- •All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Patients presenting with any of the following will not be included in the study:
- •1. Participation in other studies involving investigational drug(s) (Phases 1-4) while patient in the active treatment phase of the current study.
- •2. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Pfizer employees directly involved in the conduct of the trial.
- •3. Other severe acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •4. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
研究者
相似试验
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 20.0Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-FIPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 14.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008EUCTR2013-000691-15-GBPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 16.0Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-ESPfizer Inc, 235 East 42nd Street, New York, NY 10017820
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 21.0Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-PLPfizer Inc, 235 East 42nd Street, New York, NY 10017500